257
Participants
Start Date
April 5, 2012
Primary Completion Date
November 1, 2012
Study Completion Date
March 27, 2013
liraglutide
Liraglutide administered subcutaneously (s.c., under the skin) for 36 weeks combined with insulin therapy.
placebo
Liraglutide placebo administered subcutaneously (s.c., under the skin) for 36 weeks combined with insulin therapy.
insulin
All subjects will continue their pre-trial insulin therapy (basal, premixed or basal-bolus regimen) during the trial. Insulin dose is fixed for the first 16 weeks and for the subsequent 20 weeks, insulin dose is individually adjusted.
Novo Nordisk Investigational Site, Chuo-ku, Tokyo
Novo Nordisk Investigational Site, Ebina-shi, Kanagawa
Novo Nordisk Investigational Site, Ebina-shi
Novo Nordisk Investigational Site, Kashiwara-shi, Osaka
Novo Nordisk Investigational Site, Katsushika-ku, Tokyo
Novo Nordisk Investigational Site, Koriyama-shi, Fukushima
Novo Nordisk Investigational Site, Miyazaki
Novo Nordisk Investigational Site, Naka-shi, Ibaraki
Novo Nordisk Investigational Site, Niigata-shi, Niigata
Novo Nordisk Investigational Site, Nishinomiya-shi, Hygo
Novo Nordisk Investigational Site, Okawa-shi, Fukuoka
Novo Nordisk Investigational Site, Osaka-shi, Osaka
Novo Nordisk Investigational Site, Ota-ku, Tokyo
Novo Nordisk Investigational Site, Oyama-shi, Tochigi
Novo Nordisk Investigational Site, Ōita
Novo Nordisk Investigational Site, Sapporo-shi, Hokkaido
Novo Nordisk Investigational Site, Sapporo-shi, Hokkaido
Novo Nordisk Investigational Site, Sendai
Novo Nordisk Investigational Site, Shimotsuke-shi, Tochigi
Novo Nordisk Investigational Site, Shizuoka
Novo Nordisk Investigational Site, Takatsuki-shi, Osaka
Novo Nordisk Investigational Site, Tokyo
Novo Nordisk Investigational Site, Yokohama
Lead Sponsor
Novo Nordisk A/S
INDUSTRY